An analogue peptide from the cancer/testis antigen PASD1 induces CD8+ T cell responses against naturally processed peptide

Nicola Hardwick, Sarah Buchan, Wendy Ingram, Ghazala Khan, Gisella Vittes, Jason Rice, Karen Pulford, Ghulam Mufti, Freda Stevenson, Barbara Guinn*

*Corresponding author for this work

    Research output: Contribution to journalArticlepeer-review

    13 Citations (Scopus)

    Abstract

    We have previously identified the novel Cancer/Testis antigen PASD1 by immunoscreening a testis library with pooled acute myeloid leukemia (AML) patient sera. To develop a cytotoxic T lymphocyte (CTL)-inducing vaccine, we have now investigated the carboxy-terminal region, known to contain serological determinants, for MHC class I (HLA-A*0201)-binding peptides. Algorithmselected natural peptides failed to show detectable HLA-A*0201 binding in T2 assays. However, anchor-modified analogue peptides showed enhanced binding, with decreased off-rates. Analogue peptide-loaded antigen-presenting cells (APCs) induced IFN-γ production by T cells from normal donors and patients. In addition, peptide-specific T cells could be expanded from cancer patients by stimulation with the PASD1 analogue peptide Pa14. For clinical application, a DNA fusion gene vaccine encoding Pa14 was designed and tested in "humanized" mice. Splenocytes from vaccinated mice showed in vitro cytotoxicity against tumour cells, either exogenously loaded with the corresponding wild-type peptide (Pw8) or expressing endogenously processed PASD1 protein. We show for the first time that a DNA vaccine encoding an altered PASD1 epitope can induce CTLs to target the natural peptide expressed by human tumour cells.

    Original languageEnglish
    JournalCancer immunity
    Volume13
    Issue number3
    Publication statusPublished - 2013

    Keywords

    • Acute myeloid leukemia
    • Analogue peptide
    • DNA vaccine
    • Immunotherapy
    • PASD1

    Fingerprint

    Dive into the research topics of 'An analogue peptide from the cancer/testis antigen PASD1 induces CD8+ T cell responses against naturally processed peptide'. Together they form a unique fingerprint.

    Cite this